AGM/EGMMay 14, 2026, 10:27 AM
Mereo BioPharma Shareholders Approve All AGM Resolutions
AI Summary
Mereo BioPharma Group plc held its 2026 Annual General Meeting of Shareholders on May 14, 2026, where all proposed resolutions were passed. Shareholders approved the annual report and accounts, re-appointed PricewaterhouseCoopers LLP as auditors, and authorized the Audit and Risk Committee to determine auditor remuneration. Additionally, the directors' remuneration report and policy were approved, along with the compensation of named executive officers on an advisory basis. Shareholders also re-elected three directors and authorized the directors to allot shares and allot shares for cash on a non-pre-emptive basis.
Key Highlights
- Shareholders adopted the annual report and accounts for the year ended December 31, 2025, with 98.29% votes for.
- PricewaterhouseCoopers LLP was re-appointed as auditors with 98.59% votes for.
- The Audit and Risk Committee was authorized to determine PwC's remuneration with 98.22% votes for.
- The directors' remuneration report and policy were approved with 93.35% and 91.74% votes for, respectively.
- Compensation of named executive officers was approved on an advisory basis with 91.71% votes for.
- Justin Roberts, Dr. Daniel Shames, and Marc Yoskowitz were re-appointed as directors with over 93% votes for each.
- Directors were authorized to allot shares up to a nominal amount of A 3,591,354.73 with 80.54% votes for.
- Directors were authorized to allot shares for cash on a non-pre-emptive basis up to A 3,591,354.73 with 80.59% votes for.
Price Impact
More from MREO